SS Innovations International (SSII) Q4 2024 earnings summary

Executive summary

• Revenue grew to $20.6M in 2024, up from $5.9M in 2023, driven by increased system and instrument sales.

• Net loss narrowed to $19.2M in 2024 from $20.9M in 2023, primarily due to higher gross profit, despite increased stock compensation and R&D expenses.

• 36 surgical robotic systems sold in 2024, with 11 installed on a pay-per-use basis; total installed base reached 62 systems by year-end.

• Company continues to focus on expanding in India and select global markets, with regulatory progress in the US and EU.

Financial highlights

• Total revenue: $20.6M in 2024, up from $5.9M in 2023; system sales accounted for $19.5M.

• Gross profit: $8.5M in 2024, up from $0.7M in 2023.

• Net loss: $19.2M in 2024, improved from $20.9M in 2023.

• Stock compensation expense: $14.3M in 2024, up from $9.7M in 2023.

• Cash and equivalents: $0.8M at year-end 2024; working capital surplus of $6.1M.

Outlook and guidance

• Plans to raise additional capital in 2025 through private or public offerings to support expansion and R&D.

• U.S. IDE study for FDA approval expected to start in Q3 2025, pending regulatory approvals.

• Continued focus on expanding installed base and recurring revenue from instruments and services.